Genmab Locations

Genmab is a leading international biotech company

It is our aspiration for the future that by 2030, our knock-your-socks-off antibody medicines (KYSO antibody medicines®) are fundamentally transforming the lives of people with cancer and other serious diseases. 

Globally, we employ more than 2,000 people at our headquarters in Denmark and our offices in the Netherlands, the United States and Japan.


Genmab A/S

Carl Jacobsens Vej 30
2500 Valby
Denmark

Phone +45 7020 2728

CVR no. 2102 3884
LEI Code 529900MTJPDPE4MHJ122

Genmab QC Lab
Baltorpvej 154
2750 Ballerup
Denmark


Genmab B.V.

Visiting Address
Uppsalalaan 15
3584 CT Utrecht
The Netherlands

Postal Address
P.O. Box 85199
3508 AD Utrecht
The Netherlands

Phone +31 30 2 123 123

CVR Utrecht 30169902
VAT no. NL8095.75.000.B.01


Genmab US, Inc.

777 Scudders Mill Road
Plainsboro, NJ 08536
USA

Phone +1 609 430 2481

Website


Genmab K.K.

35F, Midtown Tower
9-7-1 Akasaka, Minato-ku
Tokyo 107-6235
Japan

Website

Chamber of Commerce no.: 0104-01-14036



Contact us

Have a general inquiry?



Contact us for medical information and queries about a specific compound or program or how to participate in a clinical trial.


Rest assured, we will handle your personal data in accordance with our Privacy Policy.

Reporting Concerns

Our value of integrity and doing the right thing means that there may be times we need to speak up about behavior that is suspected may violate our policies, standards or even the law. If you suspect or observe such behavior, we ask our people to raise such concerns through any of the channels available. Genmab also encourages external partners, vendors and stakeholders to speak up and raise such concerns as they may relate to our business.

  • Join our mission

    Be a part of our team and help transform the future of cancer treatment

    Learn more

  • Putting our expertise to work

    See how we put our in-depth knowledge of antibody biology into action

    Learn about our science

  • News, events and more

    Get the latest stock information and news about Genmab

    Learn more

You are now leaving Genmab.com to go to our collaborator’s website. If you continue, we encourage you to read the website’s privacy and cookie policy.